BCL11A and neurodevelopmental disorder: On the contrary to BCL11A, albeit thousands of whole − exome or whole − genome sequencing studies on patients with neurodevelopmental disorders, no inactivating mutations in USP34 or in XPO1 genes have yet been reported in the literature.